Targeted cancer therapy with a 2-deoxyglucose-based adriamycin complex

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Adriamycin (ADM) is an effective chemotherapy drug but limited by cardiotoxicity and multidrug resistance.
• Targeted drug delivery systems are needed to improve ADM's therapeutic index.
• Glucose transporter 1 (GLUT1) is overexpressed in many tumor cells, presenting a potential target for drug delivery.

Purpose of the Study:

• To design and evaluate a novel ADM-based complex for targeted cancer therapy.
• To investigate the efficacy of ADM conjugated with 2-amino-2-deoxy-d-glucose and succinic acid (2DG-SUC-ADM) in targeting GLUT1-expressing tumor cells.
• To assess the complex's antitumor activity, toxicity profile, and potential to overcome multidrug resistance.

Main Methods:

• Synthesis and characterization of the 2DG-SUC-ADM complex.
• In vitro evaluation using MTT assays and confocal microscopy to assess cytotoxicity and cellular uptake in tumor and normal cells.
• In vivo studies in animal models to evaluate antitumor efficacy and organ toxicity compared to free ADM.

Main Results:

• The 2DG-SUC-ADM complex demonstrated enhanced inhibition rates against tumor cells compared to free ADM.
• Confocal images and MTT assays indicated lower toxicity of the complex towards normal cells.
• The complex showed potential in overcoming multidrug resistance and increased nuclear transport in tumor cells.
• In vivo experiments confirmed reduced organ toxicity and improved antitumor efficacy of 2DG-SUC-ADM.

Conclusions:

• The novel 2DG-SUC-ADM complex effectively targets tumor cells via GLUT1.
• This targeted conjugate exhibits improved antitumor efficacy and reduced systemic toxicity compared to free ADM.
• 2DG-SUC-ADM represents a promising therapeutic agent for overcoming multidrug resistance and enhancing cancer treatment outcomes.